• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
LBL
Click for more information
1.68% 58.5¢

LASERBOND LIMITED - Corporate Spotlight

Market Cap $68.57M  ! watchlist Created with Sketch. Add to my watchlist
Industrials

Laserbond Limited is a surface engineering company. The Company is focused on the... Laserbond Limited is a surface engineering company. The Company is focused on the development and application of materials, technologies, and methodologies to increase operating performance and wear life of capital-intensive machinery components. The Company operates through three segments: Services, Products, Technology, and Research & Development. The Services segment includes the reclamation or repair of worn components for end users, or the manufacture of products that do not incorporate LaserBond cladding applications. The Products segment is engaged in the manufacture of products incorporating LaserBond cladding applications. The Technology segment is engaged in the sale of LaserBond cladding technology and associated licensing fees and consumables supply. The Research & Development segment includes ongoing development of new or improved technology, applications, and products. It serves various industries, such as mining, drilling, mineral processing.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
58.5¢ 		Change
-0.010(1.68%) 		Mkt cap ! $68.57M
Open High Low Value Volume
59.5¢ 59.5¢ 58.0¢ $10.57K 18.20K

Buyers (Bids)

No. Vol. Price($)
3 240 58.5¢
 

Sellers (Offers)

Price($) Vol. No.
59.5¢ 4289 5
View Market Depth
Last trade - 15.29pm 07/10/2024 (20 minute delay) ?
LBL (ASX) Chart

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.
Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program Arika Resources Ltd has received commitments from investors in support of a Placement worth $3.2 million to support gold exploration in WA
Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03 Nyrada Inc has completed an in-vivo micronucleus on the effects of its NYR-BI03 drug on rats, suggesting it causes no genetic damage
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.